Korea Just Built the Best Blood Test for Colorectal Cancer — What It Means Globally

The 40% Problem

South Korea screens for colorectal cancer at roughly 40% — the lowest rate among all major cancer programs. The reason is not confusion about the disease. It is the test itself.

The national program relies on a fecal occult blood test, which requires patients to collect stool samples, return them within a narrow window, and then endure a colonoscopy if the result is positive. Both steps involve social friction, physical discomfort, and scheduling logistics that most people find worth avoiding. So they do.

A research team at Seoul Asan Hospital has now published what looks like a structural fix for that participation gap.

How the Test Works

The method is straightforward in principle, precise in execution. Cancer cells shed tiny fragments of DNA into the bloodstream — circulating cell-free DNA, or cfDNA. These fragments carry molecular signatures that differ from those produced by healthy cells: their length profile, their terminal structures, their distribution across the genome. An AI model trained on next-generation sequencing data can read those patterns and classify whether cancer is present.

Seoul Asan Hospital applied this approach to 1,677 people: 302 with colorectal cancer, 108 with advanced adenomas (precancerous polyps with high-risk features), and 1,267 healthy controls. The results came out in August in the American Journal of Gastroenterology.

The Numbers

The headline figure is sensitivity: 90.4%. That means roughly nine out of ten people with colorectal cancer were correctly identified. The test detected 84.2% of Stage 1 cases, 85.0% of Stage 2, 94.4% of Stage 3, and 100% of Stage 4. For context, the fecal occult blood test used in South Korea’s national screening program catches roughly 70–80% of cancers — and only 25–40% of advanced adenomas.

Specificity was 94.7%. Out of 100 healthy people tested, approximately five would receive a false-positive result and be sent for colonoscopy. That is not trivial at a population level, but it is manageable if the blood test acts as a triage filter rather than a definitive diagnosis.

The advanced adenoma detection rate of 58.3% is arguably the more interesting number. Those polyps are the lesions that turn into cancer over five to ten years. Catching them earlier is where prevention lives. The existing stool test misses more than half of them.

Who Wins, Who Loses

The immediate winners are patients who would have skipped screening anyway. A blood draw takes fifteen minutes and requires no prep. In countries where colonoscopy access is limited or where cultural barriers reduce uptake — the United States, much of Southeast Asia, parts of Europe — this is not a marginal improvement. It is a pathway shift.

The losers are procedural. Endoscopy manufacturers, sedation services, and the hospital infrastructure built around colonoscopy-capacity planning will face long-term disruption if screening algorithms move upstream to blood tests first. That does not mean colonoscopy disappears. It means its role changes from universal screening tool to targeted follow-up for positive blood tests.

Lab corporations already active in liquid biopsy — GRAIL, Exact Sciences, Thermo Fisher — should take note. GRAIL’s Galleri test, which analyzes methylation patterns in cell-free DNA across dozens of cancer types, launched in the United States in 2024 but has struggled with commercial uptake and reimbursement questions. The Seoul Asan team’s approach is cancer-type-specific and appears optimized for colorectal outcomes. That narrow focus may be a competitive advantage rather than a limitation: higher sensitivity in a defined population is easier to get reimbursed for than a broader, less-proven one.

The Regulatory and Commercial Path

A research-grade sensitivity of 90.4% is not yet a regulatory-grade product. The team itself was careful to say the test does not yet replace colonoscopy for national screening programs. What it demonstrates is that the diagnostic ceiling is higher than previously believed for a blood-only approach. The question is whether that performance holds in real-world populations — people with inflammatory bowel disease, liver cirrhosis, and other conditions that can independently raise cfDNA levels — and whether it can be deployed at scale.

South Korea’s pharmaceutical and diagnostic regulatory pathway tends to be faster than the FDA’s for approved technologies, particularly when the clinical evidence base is strong. A Korean marketing authorization could arrive within two to three years. The FDA route would likely require a larger prospective validation study before clearance, putting commercial availability in the United States closer to five to seven years from now.

Reimbursement is the harder bottleneck. Even with superior sensitivity, payers will want cost-effectiveness data: does replacing or supplementing stool-based screening with a blood test save money over a ten-year horizon by catching earlier-stage cancers? The Seoul Asan study did not address that question directly.

Why This Matters Beyond Korea

Colorectal cancer is the third most common cancer worldwide and the second leading cause of cancer death. Incidence is rising in younger adults — South Korea reported increasing cases among people in their twenties and thirties, a trend mirrored in many high-income countries. Screening guidelines in the United States recently lowered the recommended starting age from 50 to 45. Millions of additional people are now entering screening programs annually, and the bottleneck remains the same: colonoscopy capacity and patient willingness.

A blood test that catches nine out of ten cancers and half of the precancerous lesions that precede them could change the economics and logistics of screening programs in ways that extend far beyond South Korea. It could also reshape the public health conversation in countries where colorectal cancer screening rates lag — India, Brazil, Nigeria, where colonoscopy infrastructure is thin and stool-based testing has never achieved meaningful penetration.

The test is not a cure. It is a filter — and a sharper one than what the world currently uses. Filters determine what flows through the rest of the system. This one could let significantly more early-stage cancer reach treatment earlier.

The Real Test Ahead

The Seoul Asan Hospital team has published a strong single-center result. What comes next is the hard part: prospective multi-center validation, health-economic modeling, and regulatory submissions. None of those steps are guaranteed.

But the direction is clear. Liquid biopsy for colorectal cancer is moving from research protocol toward clinical reality, and South Korea is not just participating — it is leading. If this test clears the remaining hurdles, the global screening landscape for the most common preventable cancer will look very different by the early 2030s.